Enzene Premieres Nex Partnership Program at BIO 2026

Why This Matters: Check out all our BIO 2026 coverage here.

Enzene unveiled its comprehensive, end-to-end Nex partnership program at the BIO International Convention in San Diego on June 23.

The initiative allows governments, institutions, and biopharmaceutical organizations alike to establish world-class biosimilar manufacturing in their home territories. Enzene provides the technology, expertise, and pipeline behind the operation.

Crucially, this cuts $200 to $300 million in capital needs for a conventional fed-batch facility to $60 to $70 million.

Talking Nex with Enzene CEO

Following the Nex launch, Contract Pharma spoke exclusively with Enzene CEO Himanshu Gadgil, PhD, about the new program’s potential impact.

Gadgil said whether a partner is a smaller, early-stage company or a larger one, they can access a state-of-the-art platform.

“We want to expand our network globally, go all over the world,” Gadgil said. “There are pockets in the world where it’s not just the platform, but also skill development that becomes important. So we are offering an end-to-end solution.”

According to Gadgil, part of Enzene’s portfolio are biosimilars already approved in India that can be manufactured locally and marketed. This allows clients to go from zero to being a fully operational biologics manufacturing company in less than four years.

It fits with Enzene’s mission of being a CIDMO, or “continuously innovative” development and manufacturing organization.

“We want to not just be a CDMO, but really anchor in on innovation,” Gadgil said.

NJ Facility Set for Expansion

Gadgil mentioned Enzene’s facility in Hopewell, NJ, for which the ribbon-cutting was held in September 2025, is now fully operational. So far, it has gotten a lot of interest from clients, and there are now plans to expand.

“We will put additional suites in New Jersey in the next 18 months or so,” Gadgil said. “We expect to double our capacity there.”